Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CPRX – Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.
CPRX
$20.82
Name : Catalyst Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,548,180,736.00
EPSttm : 1.65
finviz dynamic chart for CPRX
Catalyst Pharmaceuticals, Inc.
$20.82
0.43%
$0.09

Float Short %

7.76

Margin Of Safety %

27

Put/Call OI Ratio

1.21

EPS Next Q Diff

-0.23

EPS Last/This Y

0.96

EPS This/Next Y

0.16

Price

20.82

Target Price

34.29

Analyst Recom

1.14

Performance Q

-3.72

Relative Volume

0.81

Beta

0.78

Ticker: CPRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08CPRX20.080.960.1613161
2025-09-09CPRX19.980.960.0313172
2025-09-10CPRX19.720.950.0513246
2025-09-11CPRX20.250.890.0013688
2025-09-12CPRX19.980.870.0913839
2025-09-15CPRX19.750.860.6313975
2025-09-16CPRX20.070.860.1614515
2025-09-17CPRX20.020.840778637384580.3679245283018914752
2025-09-18CPRX20.410.830.0614905
2025-09-22CPRX20.031.920.279415
2025-09-23CPRX19.881.830.639605
2025-09-24CPRX19.681.790.069739
2025-09-25CPRX19.141.630.5510101
2025-09-26CPRX19.521.620.0410136
2025-09-29CPRX19.541.510.1410449
2025-09-30CPRX19.711.500.0510496
2025-10-01CPRX20.911.510.2010498
2025-10-02CPRX20.841.330.0311201
2025-10-03CPRX20.841.200.3011780
2025-10-06CPRX20.741.152.5112246
2025-10-07CPRX20.821.210.1812763
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08CPRX20.08-6.069.32.34
2025-09-09CPRX20.00-6.072.02.34
2025-09-10CPRX19.72-6.067.62.34
2025-09-11CPRX20.25-6.084.82.34
2025-09-12CPRX19.98-6.067.72.34
2025-09-15CPRX19.76-6.069.22.34
2025-09-16CPRX20.07-6.080.52.34
2025-09-17CPRX20.04-6.073.12.34
2025-09-18CPRX20.41-6.081.92.34
2025-09-19CPRX19.78-6.060.72.34
2025-09-22CPRX20.05-6.079.52.34
2025-09-23CPRX19.78-6.067.82.34
2025-09-24CPRX19.68-6.071.42.34
2025-09-25CPRX19.13-6.061.22.34
2025-09-26CPRX19.52-6.082.72.34
2025-09-29CPRX19.53-6.074.02.34
2025-09-30CPRX19.72-6.077.32.34
2025-10-01CPRX20.92-6.0100.42.34
2025-10-02CPRX20.82-6.071.92.34
2025-10-03CPRX20.83-6.073.62.34
2025-10-06CPRX20.75-6.071.82.34
2025-10-07CPRX20.82-6.075.62.34
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08CPRX-5.733.088.02
2025-09-09CPRX-5.733.088.02
2025-09-10CPRX-5.983.088.02
2025-09-11CPRX-5.983.087.11
2025-09-12CPRX-5.983.087.11
2025-09-15CPRX-5.983.107.12
2025-09-16CPRX-5.933.107.12
2025-09-17CPRX-5.933.107.12
2025-09-18CPRX-5.933.107.12
2025-09-19CPRX-5.933.107.12
2025-09-22CPRX-5.933.107.12
2025-09-23CPRX-5.933.107.12
2025-09-24CPRX-5.933.107.12
2025-09-25CPRX-5.933.107.76
2025-09-26CPRX-5.933.107.76
2025-09-29CPRX-5.933.107.76
2025-09-30CPRX-5.933.107.76
2025-10-01CPRX-5.933.107.76
2025-10-02CPRX-5.933.107.76
2025-10-03CPRX-5.933.107.76
2025-10-06CPRX-5.932.827.76
2025-10-07CPRX-5.932.827.76
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

0.68

Avg. EPS Est. Current Quarter

0.54

Avg. EPS Est. Next Quarter

0.45

Insider Transactions

-5.93

Institutional Transactions

2.82

Beta

0.78

Average Sales Estimate Current Quarter

136

Average Sales Estimate Next Quarter

136

Fair Value

26.37

Quality Score

92

Growth Score

99

Sentiment Score

92

Actual DrawDown %

21.7

Max Drawdown 5-Year %

-45.4

Target Price

34.29

P/E

12.63

Forward P/E

12.12

PEG

1.12

P/S

4.56

P/B

2.98

P/Free Cash Flow

9.28

EPS

1.65

Average EPS Est. Cur. Y​

2.34

EPS Next Y. (Est.)

2.51

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.36

Relative Volume

0.81

Return on Equity vs Sector %

-0.8

Return on Equity vs Industry %

12.9

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.24

EBIT Estimation

75.6
Catalyst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 181
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
stock quote shares CPRX – Catalyst Pharmaceuticals, Inc. Stock Price stock today
news today CPRX – Catalyst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CPRX – Catalyst Pharmaceuticals, Inc. yahoo finance google finance
stock history CPRX – Catalyst Pharmaceuticals, Inc. invest stock market
stock prices CPRX premarket after hours
ticker CPRX fair value insiders trading